openPR Logo
Press release

Investigation announced for Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) over potential Wrongdoing

05-24-2022 06:04 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares over potential wrongdoing.

An investigation on behalf of investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Regeneron Pharmaceuticals, Inc.

Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and currently hold any of those NASDAQ: REGN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Regeneron Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.

Tarrytown, NY based Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

In 2020, The U.S. Attorney's office filed suit against Regeneron Pharmaceuticals, Inc.. The complaint alleged that Regeneron Pharmaceuticals, Inc. funneled tens of millions of dollars in kickbacks through a third-party foundation to ensure that few Medicare patients paid a co-pay on Eylea and that physicians who prescribed and purchased the drug did not have to collect Medicare co-pays from their patients. Regeneron Pharmaceuticals, Inc. allegedly paid these substantial sums only after confirming that the foundation needed the money to cover co-pays only for Eylea and not for competing drugs. The company's payments would generate a handsome return on investment, or 'ROI,' in the form of Medicare payments for Eylea. Furthermore, senior company executives allegedly took extensive measures to cover up the scheme.

Those who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) over potential Wrongdoing here

News-ID: 2633969 • Views:

More Releases from Shareholders Foundation

Ardent Health, Inc. (NYSE: ARDT) Investor Alert: Deadline in Lawsuit on March 09, 2026
Ardent Health, Inc. (NYSE: ARDT) Investor Alert: Deadline in Lawsuit on March 09 …
A deadline is coming up on March 09, 2026 in the lawsuit filed for certain investors of Ardent Health, Inc. (NYSE: ARDT) over alleged securities laws violations by Ardent Health, Inc. Investors who purchased shares of Ardent Health, Inc. (NYSE: ARDT) have certain options and there are strict and short deadlines running. Deadline: March 09, 2026. Ardent Health, Inc. (NYSE: ARDT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Investigation of potential Wrongdoing
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Investigation of potent …
An investigation on behalf of investors in shares of Sina Corporation (formerly NASDAQ: SINA) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors inSina Corporation (formerly NASDAQ: SINA shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in Sina Corporation (formerly NASDAQ:
Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) shares should contact the Shareholders Foundation
Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) s …
An investor, who purchased shares of Stride, Inc. (NYSE: LRN), filed a lawsuit over alleged violations of Federal Securities Laws by Stride, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Stride, Inc. (NYSE: LRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 12, 2026. NYSE: LRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders

All 5 Releases


More Releases for Regeneron

Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • …
The qualitative latest Research report (2026-2033) on the Block Graft Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. ➤ Request a Sample Copy (Complete TOC, Tables
Myopic macular degeneration Market: Epidemiology, Therapies, Companies, DelveIns …
Myopic macular degeneration therapies, such as EYLEA (aflibercept), VABYSMO (faricimab), and others, are expected to boost the Myopic macular degeneration Market in the upcoming years. DelveInsight has launched a new report on "Myopic macular degeneration - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myopic macular degeneration, historical and forecasted epidemiology as well as the Myopic macular degeneration market trends in the United States, EU5 (Germany,
Multiple Myeloma Market on Track for Major Expansion by 2034, According to Delve …
The Key Multiple Myeloma Companies in the market incude - Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others. The Multiple Myeloma market is expected to surge due to the disease's increasing
Filariasis Market Outlook Report 2032 | AstraZeneca, GlaxoSmithKline, Sanofi, Re …
DelveInsight's "Filariasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Filariasis, historical and forecasted epidemiology, as well as the Filariasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Filariasis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Filariasis market size from 2019 to 2032, segmented
Oral Antiviral Medicine Market Thriving at a Tremendous Growth | MSD, GSK, Regen …
Global Oral Antiviral Medicine Market Growth 2022-2028 , Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider Oral Antiviral Medicine market, and
Investigation announced for Investors in shares of Regeneron Pharmaceuticals, In …
An investigation was announced concerning potential securities laws violations by Regeneron Pharmaceuticals, Inc. in connection with certain financial statements. Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Regeneron Pharmaceuticals, Inc. regarding its business, its prospects and its operations were